Conmed Stock

Conmed Equity

The The Equity of Conmed (CNMD) as of Aug 5, 2026 is 1.03 B USD. In the previous year, The Equity was 962.68 M USD — a change of 7.31% (higher).

Equity

1.03 BUSD

YoY

7.31%

Last updated:

In 2026, Conmed's equity was 1.03 B USD, a 7.31% increase from the 962.68 M USD equity in the previous year.

Access this data via the Eulerpool API

Conmed Stock analysis

What does Conmed do? Conmed Corporation is a leading medical technology company that offers a wide range of surgical instruments and devices for the fields of gastroenterology, endoscopy, orthopedics, gynecology, and electro surgery. The company was founded in 1970 and is headquartered in Utica, New York. The history of Conmed Corp began with the founding of Consolidated Medical Equipment, Inc. (CME) in 1970. The company initially started its business with the distribution of surgical instruments and devices for medical applications and quickly expanded in this field. In the 1980s, the company went public. In the 1990s, the company changed its name to Conmed Corporation and expanded its activities into the field of electro surgery, which has since become a major growth driver for the company. Today, Conmed Corp operates multiple manufacturing facilities worldwide and has sales offices in over 50 countries. The company is divided into four main business segments: gastroenterology, endoscopy, orthopedics, and electro surgery. The gastroenterology segment includes products for the diagnosis and treatment of gastrointestinal disorders, such as endoscopes, biopsy instruments, dilation balloons, trocars, and shears. In the endoscopy segment, Conmed Corp offers products for the diagnosis and treatment of digestive tract disorders, including endoscopes, biopsy instruments, dilation balloons, trocars, and shears. The orthopedics segment includes a wide range of surgical instruments and devices for the treatment of musculoskeletal disorders, including implants, bandages, bone plates, intramedullary nails, and others. Finally, the electro surgery segment is the fastest-growing segment of Conmed Corp and includes a wide range of devices for precision surgery, including electrocautery, electro surgery, endoscopy, and laparoscopy devices. Conmed Corp aims to develop innovative medical technologies that meet the needs of patients and healthcare professionals. The company places great emphasis on producing high-quality products that are reliable and safe. Conmed Corp is a successful company that continues to evolve and expand its product range to meet the rapidly evolving needs of the medical community. Conmed is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Conmed's Equity

Conmed's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Conmed's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Conmed's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Conmed's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Conmed’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Conmed stock

The Equity of Conmed is 1.03 B USD in 2026.

The Equity of Conmed changed from 962.68 M USD to 1.03 B USD, representing a 7.31% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Equity Conmed since 2006 – with annual values, charts, and detailed analysis.

The Equity's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's Conmed historically and in real time.

Access this data via the Eulerpool API

Balance Sheet — Conmed

All Key Metrics — Conmed